Medicinrådet har vedtaget at anbefale Revlimid som livsforlængende vedligeholdelsesbehandling til patienter med knoglemarvskræft. – Sagen er endt lykkeligt, men forløbet har ikke været optimalt, siger adm. direktør i Kræftens Bekæmpelse Jesper Fisker. Den meget omtalte …
Onsdag forventes Medicinrådet at tage stilling i sagen om lægemidlet Revlimid som livsforlængende vedligeholdelsesbehandling til patienter med knoglemarvskræft. Kræftens Bekæmpelses håber, rådet vil anbefale midlet. I denne uge ser det ud til, at der omsider …
Copyright © 24NYT | 2023
| Cookie | Varighed | Beskrivelse |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
